Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 17, 2016. The document serves as a transaction notification regarding a specific corporate action involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not report consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a single share acquisition transaction.
| Metric | Value |
|---|---|
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Type | Acquisition via dividend re-investment (Deferred Annual Bonus Plan Post-Tax) |
| Share Prices | £17.0319 |
| Volumes Acquired | 32.163 and 32.345 shares |
| Transaction Date | October 13, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not provide comparative financial data or material changes to the company's overall financial position versus prior periods. The only change reported is the increase in shareholding for Ms. C Thomas (SVP, HR) resulting from the dividend re-investment plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a statutory disclosure of a specific transaction.
Key Facts for Investor Verification
- The transaction involved the acquisition of approximately 64.5 total shares by Ms. C Thomas.
- The acquisition was executed automatically through the re-investment of dividends paid on October 13, 2016.
- The transaction price was fixed at £17.0319 per share.
- This filing does not reflect any broader strategic shift or financial performance update for GSK Plc.